Envestnet Portfolio Solutions Inc. Sells 73 Shares of Repligen Co. (NASDAQ:RGEN)

Envestnet Portfolio Solutions Inc. lowered its stake in shares of Repligen Co. (NASDAQ:RGEN) by 2.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,443 shares of the biotechnology company’s stock after selling 73 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Repligen were worth $496,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently added to or reduced their stakes in RGEN. Ballentine Partners LLC lifted its position in shares of Repligen by 4.0% during the fourth quarter. Ballentine Partners LLC now owns 1,879 shares of the biotechnology company’s stock valued at $270,000 after buying an additional 72 shares during the last quarter. CIBC Asset Management Inc raised its stake in shares of Repligen by 5.0% during the 4th quarter. CIBC Asset Management Inc now owns 1,706 shares of the biotechnology company’s stock worth $246,000 after acquiring an additional 81 shares in the last quarter. MML Investors Services LLC lifted its position in Repligen by 2.7% during the third quarter. MML Investors Services LLC now owns 3,383 shares of the biotechnology company’s stock valued at $503,000 after acquiring an additional 89 shares during the last quarter. GAMMA Investing LLC boosted its stake in Repligen by 15.2% in the fourth quarter. GAMMA Investing LLC now owns 684 shares of the biotechnology company’s stock valued at $98,000 after acquiring an additional 90 shares in the last quarter. Finally, Louisiana State Employees Retirement System grew its holdings in Repligen by 0.7% in the fourth quarter. Louisiana State Employees Retirement System now owns 14,500 shares of the biotechnology company’s stock worth $2,087,000 after purchasing an additional 100 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Analyst Ratings Changes

RGEN has been the subject of several analyst reports. Canaccord Genuity Group increased their price objective on Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a report on Friday, February 21st. StockNews.com cut Repligen from a “hold” rating to a “sell” rating in a research note on Friday, February 21st. Evercore ISI assumed coverage on Repligen in a research note on Tuesday, March 18th. They set an “in-line” rating and a $155.00 price target on the stock. Royal Bank of Canada upped their price objective on shares of Repligen from $203.00 to $205.00 and gave the company an “outperform” rating in a report on Friday, February 21st. Finally, Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $178.64.

Insider Buying and Selling

In other news, Director Margaret Pax bought 250 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The stock was purchased at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This trade represents a 31.53 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Stock Down 2.2 %

RGEN stock opened at $141.95 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 10.44 and a quick ratio of 8.76. The firm’s fifty day simple moving average is $155.62 and its 200-day simple moving average is $148.36. Repligen Co. has a 12 month low of $113.50 and a 12 month high of $187.25. The company has a market capitalization of $7.97 billion, a P/E ratio of -278.33, a price-to-earnings-growth ratio of 4.54 and a beta of 0.95.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. As a group, equities research analysts forecast that Repligen Co. will post 1.72 earnings per share for the current year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.